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Abstract
Introduction: Cachexia contributes to increased mortality and reduced quality of life in Chronic Obstructive
Pulmonary Disease (COPD) and may be associated with underlying gene expression changes. Our goal was to
identify differential gene expression signatures associated with COPD cachexia in current and former smokers.
Methods: We analyzed whole-blood gene expression data from participants with COPD in a discovery cohort
(COPDGene, N = 400) and assessed replication (ECLIPSE, N = 114). To approximate the consensus definition using
available criteria, cachexia was defined as weight-loss > 5% in the past 12months or low body mass index (BMI) (< 20
kg/m2) and 1/3 criteria: decreased muscle strength (six-minute walk distance < 350m), anemia (hemoglobin < 12 g/dl),
and low fat-free mass index (FFMI) (< 15 kg/m2 among women and < 17 kg/m2 among men) in COPDGene. In ECLIPSE,
cachexia was defined as weight-loss > 5% in the past 12months or low BMI and 3/5 criteria: decreased muscle strength,
anorexia, abnormal biochemistry (anemia or high c-reactive protein (> 5mg/l)), fatigue, and low FFMI. Differential gene
expression was assessed between cachectic and non-cachectic subjects, adjusting for age, sex, white blood cell counts,
and technical covariates. Gene set enrichment analysis was performed using MSigDB.
Results: The prevalence of COPD cachexia was 13.7% in COPDGene and 7.9% in ECLIPSE. Fourteen genes were differentially
downregulated in cachectic versus non-cachectic COPD patients in COPDGene (FDR < 0.05) and ECLIPSE (FDR < 0.05).
Discussion: Several replicated genes regulating heme metabolism were downregulated among participants with COPD
cachexia. Impaired heme biosynthesis may contribute to cachexia development through free-iron buildup and oxidative
tissue damage.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is a lead-
ing causes of death worldwide, and it maintains increasing
morbidity and mortality [1]. COPD is diagnosed based on
reduced, irreversible lung function however, comorbidities
are common with COPD and negatively impact survival
[2]. Muscle wasting and cachexia are relevant comorbidi-
ties among COPD patients with prevalence increasing
with stage of illness [2]. Cachexia in COPD may be associ-
ated with underlying changes in gene expression that
could provide valuable insights for surveillance and drug
development.
Collectively, there have been limited investigations exam-
ining differential gene expression in the context of COPD
cachexia. Previous studies of gene expression changes in
COPD cachexia have had small sample sizes, non-disease
controls for comparison, employed a candidate-gene
approach, or have focused on proxies for cachexia such as
low fat-free mass index (FFMI) [3, 4]. Nonetheless, these
studies have highlighted interesting genes with relevant
biology to cachexia such as FOXO1 and FOXO3 [5]. The
candidate-gene expression approach is limited to our un-
derstanding of known biology. In contrast, the genome-
wide method is an agnostic, hypothesis-free approach, that
has elucidated novel molecular mechanisms of COPD
pathogenesis [6]. A challenge for implementing the
genome-wide approach is that a large number of study par-
ticipants are typically required to achieve a genome-wide
level of significance. Although low FFMI and low BMI are
components of the multifactorial definition of cachexia,
these measures alone are not sufficient to monitor cachexia
in the entire population at risk [7].
Our goal was to identify and explore differentially
expressed genes associated with COPD cachexia. To
achieve our objective, we utilized genome-wide expres-
sion data to conduct differential gene expression ana-
lyses aimed at deciphering the molecular mechanisms
associated with cachexia in COPD patients from
COPDGene [8]. We then tested whether significantly
differentially expressed genes would be replicated in a
second cohort of COPD patients from the ECLIPSE
study [9].
Methods
Study design and ethics
Institutional Review Board approval for all analyses was
obtained from the University of Alabama at Birmingham
and have been performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki
and its later amendments. All subjects included in this
analysis provided written informed consent prior to their
inclusion in the respective studies mentioned below. All
statistical analyses were performed in R (version 3.5.3).
Study populations
For both cohorts, COPD was defined as airflow obstruc-
tion using post-bronchodilator spirometry as GOLD grade
2 (FEV1/FVC< 0.7 and 50% < FEV1 < 80% predicted;
FEV1: forced expiratory volume in one second, FEV1/
FVC: FEV1 expressed as a percentage of forced vital cap-
acity) or higher [10]. Discovery analyses were performed in
400 participants with COPD from the COPDGene study
(NCT00608764; www.copdgene.org). COPDGene is a
multicenter, observational study intent on characterizing
progression of and genetic susceptibility to COPD, the de-
tails of which have been described previously [8]. In brief,
COPDGene enrolled Non-Hispanic White and African
American current or former smokers, with at least a 10
pack-year smoking history, aged 45 to 80 years to follow
longitudinally, with two visits 5 years apart. RNA samples
were collected at the five-year follow-up visit. Replication
analyses were performed in 114 participants with GOLD
2–4 COPD enrolled in the ECLIPSE (Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints;
SCO104960, NCT00292552; www.eclipse-copd.com) co-
hort. In ECLIPSE, phenotype data was obtained via the
database of Genotypes and Phenotypes (dbGaP accession:
phs001252.v1.p1) and gene expression data from the Gene
Expression Omnibus (GEO: GSE76705). In brief, ECLIPSE
[9] was a three-year observational study of subjects with
COPD aged 45 to 75 years with a smoking history of ten
or more pack-years. Like COPDGene, smaller numbers of
control subjects were enrolled in ECLIPSE, who were not
included in analysis. Forty-six centers across twelve coun-
tries collected data at baseline, 3 months, 6 months, and
then every 6months for three years. The main goal of
ECLIPSE was to identify biomarkers associated with the
progression of disease severity.
Phenotype data
In COPDGene, cachexia was defined at visit two, approxi-
mately five years from baseline, as either self-reported,
unintentional weight loss greater than 5% in the past year
or low BMI (< 20 kg/m2) in addition to one of three criteria:
low 6MWD (< 350m; a surrogate for decreased muscle
strength), anemia (hemoglobin< 12 g/dl) or low FFMI
(FFMI < 15 kg/m2 among women and FFMI < 17 kg/m2
among men). Low 6MWD and anemia were classified using
visit two data. FFMI was derived from an algorithm incorp-
orating pectoralis muscle area on baseline chest computed
tomography scans [11].
In ECLIPSE, cachexia was defined according to the
Evans consensus definition [12] at year 1 of the study as:
weight loss greater than 5 % in the past 12 months or
low BMI (< 20 kg/m2) and at least three of the five
criteria: low six-minute walking distance (a surrogate for
decreased muscle strength), anorexia, abnormal bio-
chemistry (anemia or high CRP), fatigue, and low FFMI
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[12]. FFM was measured using bioelectrical impedance.
Low FFMI was defined as < 15 kg/m2 among women
and < 17 kg/m2 among men. Abnormal biochemistry was
defined as having anemia (hemoglobin< 12 g/dl) or high
CRP (> 5mg/l). Six-minute walking distance (6MWD) <
350m [13] was used to classify decreased muscle strength
[13]. Anorexia and fatigue were only available at baseline
and end of study. Anorexia was classified if a participant
reported not feeling like eating for 3 or more days in the
week prior to either the baseline or 3-year follow-up visit.
Fatigue was defined at either baseline or 3-year visits as a
FACIT (Function Assessment of Chronic Illness Therapy)
questionnaire score less than 34 [14].
Gene expression data
In COPDGene, RNA-sequencing was performed using
whole-blood samples collected at visit 2 (~Year 5) from
400 current or former smokers with COPD. RNA-
sequencing alignment and quality control was previously
describe in detail [6]. Transcripts were included in analyses
if expressed at levels > 1 count per million mapped reads
in > 10 subjects. Potential batch effects and unknown arti-
facts were removed using the SVAseq R package [15] to es-
timate surrogate variables (SV’s) while accounting for the
presence of known covariates: age, sex, library construction
batch, and white blood cell (WBC) count percentages.
Principle component analysis (PCA) was performed on SV
residualized expression data to ensure minimal systematic
bias (Supplementary Figure 1).
In ECLIPSE, normalized gene expression data was ob-
tained from GEO (GEO: GSE76705). Sample preparation
and quality control for gene expression data obtained from
ECLIPSE have been previously described [16, 17]. Briefly,
gene expression in ECLIPSE was obtained from whole-
blood samples collected at baseline and profiled using the
Affymetrix Human U133 Plus2 array. Gene expression data
were log-transformed, normalized, then background
corrected through multi-array averaging and quantile
normalization using the affy Bioconductor package [18].
Probes with low variance (< 50%) and those which did not
annotate within a specific gene were removed, leaving a
dataset of 21,156 probes for analysis in 114 COPD cases.
The amount of missing data for each probe was assessed for
quality control, and no probes were removed due to miss-
ingness, defined as missing in more than 3% of samples.
Differential gene expression analysis
Differential gene expression analysis comparing cachec-
tic and non-cachectic COPD patients from COPDGene
was performed using the voom [19] and limma [20] R
packages. Linear regression models were fit for each
transcript and adjusted to control for age, gender, white
blood cell (WBC) percentages, and significant SVs (N =
27). Significance for differentially expressed transcripts
in COPDGene was defined as an FDR p-value < 0.05 ad-
justed for number of transcripts (Fig. 1).
In ECLIPSE, only probes mapping to a gene that was
significantly differentially expressed in COPDGene were
evaluated using linear regression models. A P < 0.05 was
considered to be a significant replication in ECLIPSE.
Models were adjusted to control for age, gender, and
WBC percentages. In instances were multiple probes
mapped to a single gene, the probe with the highest
mean expression value was selected [21].
Gene overlap enrichment between genes significantly
differentially expressed in COPDGene and ECLIPSE
were calculated using the GeneOverlap R package [22]
using a two-tailed Fisher’s exact to calculate the FDR
corrected p-value between overlapping genes.
Pathway analysis
Gene set enrichment analysis (GSEA) of genes significantly
differentially expressed in COPDGene and for those that
replicated in ECLIPSE was performed using the Molecular
Signatures Database (MSigDB) v6.1 [23]. This included
gene set collections comprised of the hallmark gene set
(N = 50 gene sets), curated gene sets (N = 4762 gene sets),
Gene Ontology (GO) gene sets (N = 5917 gene sets), onco-
genic signatures (N = 189 gene sets), and immunogenic
signatures (N = 4872 gene sets). GSEA significance was
defined as having an FDR-q p-value less than 0.05.
Results
Demographics
The prevalence of cachexia was 13.7% in COPDGene
participants with COPD (Table 1).
There was no significant difference between the cach-
ectic and non-cachectic COPD participants in COPD-
Gene in terms of age (Table 1). On average, cachectic
COPD subjects were more likely to be female (52.7% vs.
37.7%, p = 0.049), have lower lung function (FEV1%
Table 1 COPDGene Sample Demographics. Descriptive values
for COPD patients (N = 400) in COPDGene with gene expression
data by Cachectic (N = 55) and Non-Cachectic (N = 345) co-
morbid status. Unless otherwise noted values denote mean (SD)
Demographic Cachectic Non-Cachectic P-value
N (%) 55 (13.7) 345 (86.3)
Age 68.1 + 9.2 68.8 + 8.1 0.52
Sex N(%) 0.049
Male 26 (47.3) 215 (62.3)
Female 29 (52.7) 130 (37.7)
FEV1pp (%) 44.0 + 18.1 54.0 + 18.1 < 0.001
Pack Years Smoking 46.8 + 19.2 53.5 + 26.0 0.027
BMI (kg/m2) 22.0 + 4.9 28.8 + 6.0 < 0.001
FEV1pp – Forced Expiratory Volume in One Second Percent Predicted, BMI -
Body Mass Index, SD – Standard Deviation
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predicted 44.0 + 18.1 vs. 54.0 + 18.1, p < 0.001), and had
less intensive smoking histories (46.8 + 19.2 vs. 53.5 + 26.0
pack years, p = 0.027) (Table 1). Cachectic COPD partici-
pants had lower BMI compared to non-cachectic COPD
participants (22.0 + 4.9 vs 28.8 + 6.0, p < 0.001) (Table 1).
As replication analyses were performed using data from
the ECLIPSE study, we compared the characteristics of
COPD participants included in the analyses in both studies
in terms of age, sex, smoking duration, lung function, and
BMI (Table 2). There were no significant differences be-
tween participants in COPDGene and ECLIPSE in terms
of cumulative smoking exposure, lung function (FEV1 per-
cent predicted), and BMI (Table 2). COPD participants in
ECLIPSE were slightly younger (64.9 ± 5.3 vs. 68.7 ± 8.2
years, p < 0.05).
Differential gene expression in COPDGene
In COPDGene, 23 transcripts were significantly differen-
tially expressed between cachectic and non-cachectic
COPD participants (Table 2). Of these genes, 22 were
downregulated among those with COPD cachexia.
Replication in ECLIPSE
In ECLIPSE, only 14 of the 23 significantly differentially
expressed genes in COPDGene were measured on the Affy-
metrix expression array. All of which were also significantly
differentially expressed among participants with COPD
cachexia in ECLIPSE (Table 3). These genes include
ALAS2, ANK1, ASCC2, CDC34, GUCD1, PLEK2, TNS1,
SPTB, TRIM58, RILP, PPP2R5B, SMIM24, SLC25A39, and
UBXN6 (Table 3). In addition, gene set overlap enrichment
analysis of significantly differentially expressed genes in
COPDGene and ECLIPSE identified these 14 genes as hav-
ing a significant overlap (FDR-p = 7.9 × 10− 11).
Pathway analysis
The 23 differentially expressed genes associated with COPD
cachexia in the discovery cohort were significantly enriched
for gene sets involved in heme metabolism (Hallmark
Fig. 1 Volcano plot of differential gene expression of cachectic vs. non-cachectic COPD patients from COPDGene. The plot shows the log2 fold
change on the x-axis and the unadjusted p-value on the y-axis (on the -log10 scale). Blue dots represent genes with a fold changed greater than
or equal to + 1 and a p-value < 0.05
Table 2 Sample Demographics. Descriptive values for
COPDGene and ECLIPSE subjects with COPD and gene
expression data. Unless otherwise noted values denote
mean + (SD)
Demographic COPDGene Study ECLIPSE Study P-value
N 400 114
Age 68.7 + 8.2 64.9 + 5.3 p < 0.05
Sex N(%) p < 0.05
Male 241(60.3) 78 (68.4)
Female 159 (39.7) 36 (31.6)
FEV1pp (%) 52.7 + 18.4 50.5 + 15.1 0.20
Pack Years Smoking 52.6 + 25.3 47.6 + 28.3 0.08
BMI (kg/m2) 27.9 + 6.3 27.0 + 5.5 0.11
FEV1pp – Forced Expiratory Volume in One Second Percent Predicted, BMI -
Body Mass Index, SD – Standard Deviation
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Heme Metabolism, FDR p-value = 5.92 × 10− 7) and heme
biosynthesis (GO Heme Biosynthetic Process, FDR p-
value = 3.85 × 10− 2), among others (Table S2). The 14 sig-
nificantly differentially expressed COPD cachexia genes in
the discovery which replicated were enriched with genes in-
volved in heme metabolism (Hallmark Heme Metabolism,
FDR-p = 4.50 × 10− 8; ALAS2, ANK1, TNS1, SPTB, TRIM58,
PPP2R5) and heme biosynthesis (GO Heme Biosynthetic
Process, FDR-p = 2.45 × 10− 2; ALAS2, SLC25A39), among
others (Table 4). ASCC2, CDC34, UBXN6, PLEK2, RILP,
SMIM24 and GUCD1 were not enriched in any significant
pathways.
Discussion
In this study, we identified novel gene expression signa-
tures associated with COPD cachexia in two independent
cohorts of participants with moderate to severe COPD.
All significant genes were downregulated among cachectic
COPD patients. Several of these genes are involved in the
regulation of heme metabolism (ALAS2, ANK1, TNS1,
SPTB, TRIM58, PPP2R5) and biosynthesis (ALAS2 and
SLC25A39). These findings may have implications for
cachexia disease surveillance and drug development. Im-
paired heme metabolism and biosynthesis, decreased hep-
cidin production, and hemolysis may contribute to COPD
cachexia through the induction of iron overloading lead-
ing to oxidative tissue damage, mitochondrial dysfunction,
and aberrant repair (Fig. 2).
Disruption of iron homeostasis in lung disease overall
has received attention as a potential pathobiological mech-
anism in COPD [24–26]. Recently, Sato et al. [26] reported
mice fed an iron deficient diet were more susceptible to
Table 3 Genes significantly differentially expressed between cachectic1 and non-cachectic COPD
Gene Name COPDGene ECLIPSE3
Log FC FDR-value2 Log FC FDR-value2
ALAS2 5′-Aminolevulinate Synthase 2 − 0.42 0.015 −0.98 0.00010
ANK1 Ankyrin 1, Erythrocytic −0.23 0.036 −0.80 0.0060
ASCC2 Activating Signal Cointegrator 1 Complex Subunit 2 −0.21 0.0074 −0.53 0.012
BACH2 BTB Domain and CNC Homolog 2 −0.17 0.0074 – –
CDC34 Cell Division Cycle 34 −0.22 0.011 −0.58 0.0066
CSF2RB Colony Stimulating Factor 2 Receptor Beta Common Subunit −0.12 0.036 – –
ENSG00000231393 Novel Transcript −0.45 0.036 – –
ENSG00000236283 Novel Transcript −0.68 0.046 – –
GUCD1 Guanylyl Cyclase Domain Containing 1 −0.17 0.0088 −0.36 0.0060
IGHG1 Immunoglobulin Heavy Constant Gamma 1 0.59 0.0074 – –
MIR186 MicroRNA 186 −0.48 0.0074 – –
PLEK2 Pleckstrin 2 −0.33 0.044 − 1.04 0.0027
PPP2R5B Protein Phosphatase 2 Regulatory Subunit B’Beta −0.26 0.012 −0.30 0.012
RILP Rab Interacting Lysosomal Protein −0.24 0.012 −0.51 0.012
RNF149 Ring Finger Protein 149 −0.087 0.0078 – –
SLC25A39 Solute Carrier Family 25 Member 39 −0.22 0.0074 −0.57 0.0053
SMIM24 Small Integral Membrane Protein 2 −0.66 0.0074 −0.71 0.025
SPTB Spectrin Beta, Erythrocytic −0.33 0.0074 −0.77 0.0060
TICAM1 Toll Like Receptor Adaptor Molecule 1 0.48 0.016 – –
TNS1 Tensin 1 −0.31 0.018 −1.07 0.0010
TRIM58 Tripartite Motif Containing 58 −0.34 0.0074 −0.90 0.0036
TRPM2 Transient Receptor Potential Cation Channel Subfamily M Member 2 0.30 0.016 – –
UBXN6 UBX Domain Protein 6 −0.21 0.032 −0.55 0.012
FC Fold Change
1In COPDGene, cachexia was defined at visit two, approximately five years from baseline, as either unintentional weight loss greater than 5% in the past year or
low BMI in addition to one of three criteria: low 6MWD, anemia or low FFMI. Unintentional weight loss was calculated at visit two using self-reported
unintentional weight loss in the past year. Low 6MWD and anemia were classified using visit two data. FFMI was derived from pectoralis muscle area on baseline
chest computed tomography scans [18]. In ECLIPSE, cachexia was defined as weight loss greater than 5 % in the past 12 months or low BMI and at least three of
the five criteria: low six-minute walking distance, anorexia, abnormal biochemistry (anemia or high CRP), fatigue, and low FFMI
2In COPDGene, FDR was calculated based on 65,988 transcripts. In ECLIPSE, FDR was calculated based on N = 14 significantly differently expressed probes present
in COPDGene
3Missing values were not significantly replicated in ECLIPSE
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cigarette smoke developing severe emphysema and lung
hyperinflation. This finding conflicts with an earlier report
by Cloonan et al. [25] where mice fed an iron deficient diet
or given an iron chelator were less susceptible to cigarette
smoke exposure. In keeping with Cloonan et al. [25], our
findings may point to a role for iron toxicity through im-
paired heme biosynthesis and metabolism as a number of
genes involved with these processes were downregulated in
COPD cachexia (Fig. 2). Heme is an essential component
of hemoglobin and anemia is a component of the criteria
used to define cachexia. Anemia is a common co-
morbidity in COPD [24]. We performed a sensitivity ana-
lysis to evaluate whether the 23 genes significantly differen-
tially expressed among subjects with COPD cachexia were
also associated with anemia and found no significant asso-
ciation (data not shown). A genome-wide expression study
Table 4 Gene Set Enrichment Analysis of Genes Associated with COPD Cachexia in COPDGene which replicated in ECLIPSE
Gene Set Name N Genes in Set N Genes Overlap FDR p-value
GSE34205 RSV vs Flu INF Infant PBMC Up 200 7 3.27 × 10−10
Hallmark Heme Metabolism 200 6 4.50 × 10−8
Valk AML Cluster 7 28 3 0.00023
GSE34205 Healthy vs RSV INF Infant PBMC Down 200 4 0.00067
Chyla CBFA2T3 Targets Down 242 4 0.0011
Steiner Erythrocyte Membrane Genes 15 2 0.017
GO Heme Biosynthetic Process 20 2 0.025
Welch GATA1 Targets 22 2 0.025
PRC2 SUZ12 Up V1 Up 191 3 0.025
REACTOME Interaction Between L1 AND Ankyrins 23 2 0.025
GSE16522 Anti CD3CD28 Stim VS Unstim Memory CD8 T-Cell Up 199 3 0.025
Valk AML Cluster 8 26 2 0.025
GO Tetrapyrrole Biosynthetic Process 27 2 0.025
GO Heme Metabolic Process 29 2 0.029
GO Porphyrin Containing Compound Metabolic Process 36 2 0.041
Hofmann Cell Lymphoma Down 39 2 0.046
Fig. 2 Summary of key findings in relationship to a putative role of iron in COPD cachexia. Genes in blue are significantly downregulated in
COPD cachexia in manuscript analyses
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of skeletal muscle biopsies from upper gastro-intestinal
cancer patients highlighted ALAS1 as downregulated in pa-
tients with cancer cachexia [27]. ALAS2 and ALAS1 encode
the same enzyme, 5′-Aminolevuilnnate Synthetase, which
plays a key role in heme synthesis [28]. Previous studies
have demonstrated that ALAS1 and ALAS2 expression
levels are increased during erythropoiesis in healthy indi-
viduals [28]. ALAS2 is erythroid-specific whereas ALAS1 is
expressed in many tissues, including skeletal muscle. This
may indicate defective heme biochemistry has ramifica-
tions outside of circulating red blood cells which could be
relevant to both cancer and COPD cachexia. SLC25A39
encodes the solute carrier family 25 member 39, a mito-
chondrial membrane protein which plays a role in iron
homeostasis and metabolism [29]. Specifically, SLC25A39 is
involved in iron transportation and transfer, and interrup-
tions in SLC25A39 biogenic activity have been shown to re-
sult in iron overloading [29]. ANK1 (encodes ankyrin 1)
and SPTB (encodes the erythrocytic protein spectrin beta)
are involved in erythrocyte membrane stability. Mutations
in ANK1 and SPTB have been linked to erythrocyte mem-
brane disorders including hereditary spherocytosis, in
which clinically significant iron overload is commonly seen
[30]. PPP2R5B (protein phosphatase 2 regulatory subunit
B’beta) and TRIM58 (tripartite motif containing 58) func-
tion as regulators of erythropoiesis and mutations in these
genes can lead to defective erythropoiesis and [31, 32] iron
overloading [33]. TNS1 (Tensin 1) plays a role in heme me-
tabolism and functions in the formation of fibrillar adhe-
sion in muscle. Previous studies have identified an
association between genetic variants in TNS1 and elevated
risk of COPD and lung function decline [34]. Transcrip-
tomic analysis has identified TNS1 as downregulated and
differentially expressed in hypoxic alveolar cells [35]. Lung
parenchymal destruction in COPD makes it difficult for the
body to take in sufficient oxygen and can lead to hypox-
emia (low blood oxygen saturation). Hypoxemic COPD pa-
tients often present with polycythemia, which suggests
increased production of erythrocytes may be one mechan-
ism for the body to maximize delivery of oxygen from the
lungs [36]. Downregulation of TNS1 and other genes play-
ing a critical role in heme metabolism could inhibit the
body’s ability to effectively sequester the elevated levels of
iron produced leading to an excess of iron.
In our study, PLEK2 was significantly downregulated in
cachectic COPD patients. PLEK2 encodes pleckstrin-2, a
protein playing a critical role in the protection of erythro-
blasts from oxidative damage [37]. Specifically, PLEK2
functions in the structural organization of the erythroblast
to prevent the localization of cofilin (an actin-binding pro-
tein) to the mitochondria where it induces apoptosis [28,
37]. Previous studies have demonstrated pleckstrin-2
knockout results in erythrocyte apoptosis and inhibition
of differentiation, a precursor to cell-free iron loading
[37]. Our study indicates downregulation of PLEK2 could
result in increased rates of hemolysis resulting in iron
overloading (Fig. 2).
Hepcidin is essential for sequestering iron in the body
and downregulation of hepcidin has been shown to
cause severe iron overloading [38]. One gene, GUCD1,
was downregulated in cachectic COPD patients. GUCD1
(guanylyl cyclase domain containing 1) is a ubiquitous
protein that plays a role in regulating the growth of liver
cells [39]. Hepcidin, produced in liver cells, degrades fer-
roprotein, which is responsible for releasing iron from
cells [38]. Downregulation of GUCD1 in our study may
suggest one mechanism of iron-overloading due to im-
paired hepcidin production (Fig. 2).
Iron overload due to inhibited iron metabolism has been
implicated in increased production of reactive oxygen spe-
cies, mitochondrial dysfunction, and oxidative stress [24].
Interestingly, mitochondrial dysfunction is one mechan-
ism thought to contribute to the development of muscle
wasting and dysfunction in COPD via buildup of oxidative
stress [2]. In our study, the downregulation of genes in-
volved in heme metabolism and biosynthesis, hepcidin
production, and erythrocyte membrane stability may con-
tribute to iron-overloading. Iron overloading has been im-
plicated in the generation of mitochondrial dysfunction
and oxidative damage, which are hallmarks of COPD
cachexia pathogenesis (Fig. 2) [40].
Our study has several strengths and limitations. A
strength of our study is that it presents the largest
genome-wide expression study of cachexia in patients with
COPD. We took advantage of a genome-wide approach
which highlighted new candidate genes associated with
COPD cachexia such as those involved with heme bio-
chemistry. Another strength of our study was our ability to
phenotype cachexia in our replication cohort (ECLIPSE)
according to the criteria from the cachexia consensus def-
inition [12], whereas previous studies have focused on
COPD cachexia-associated proxy traits such as low FFMI
or low BMI that lack specificity. Finally, we were also able
to replicate 14 genes as a potential markers of COPD
cachexia in an independent cohort of participants with
COPD. Among the limitations, we were not able to test
whether all 23 significantly differentially regulated genes in
COPDGene replicated in ECLIPSE due to limitations with
the microarray not having probes for all 23 genes. It is pos-
sible some of these genes would also replicate but requires
further study in a COPD cohort with RNA-sequencing
data. There was also limited phenotype data available to
characterize cachexia in COPDGene to code the 5 criteria
of the consensus definition; thus, we used the maximal set
available. As not all criteria were available to categorize
cachexia using the Evans consensus definition, participants
with COPD may have been miscategorized. However, the
criteria we used to classify cachexia in ECLIPSE were
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much more stringent and we replicated 14/23 findings.
Further, unintentional weight loss in COPDGene was self-
reported, which can be unreliable. We also dichotomized
6MWD (6MWD< 350m) as a surrogate for muscle
strength which could have misclassified some participants.
Although it is reasonable to infer participants with very low
6MWD have low muscle strength, other factors such as car-
diac and pulmonary function may affect 6MWD. We also
analyzed gene expression data generated at a single time
point. A longitudinal analysis would have provided a deeper
and more powerful understanding of the changes in gene
expression over time. Future analyses could prove useful in
understanding the changes that occur over time in cachec-
tic COPD patients and even prior to the development of
cachexia to define at-risk populations. Also, we did not use
qRT-PCR to validate significant findings from COPDGene
However, our discovery analyses were performed with a
fairly large sample size of 400 COPD subjects with replica-
tion in an independent cohort of COPD subjects. Finally,
peripheral blood was used to evaluate gene expression in
cachectic COPD subjects as opposed to skeletal muscle.
However, our study replicates abovementioned findings
using skeletal muscle biopsies to evaluate gene expression
in patients with cancer cachexia [27]. Additionally, a periph-
eral blood sample is less invasive than a skeletal muscle bi-
opsy, an important factor to consider due to the advanced
age and accompanying frailty in COPD patients [1].
Conclusions
In conclusion, this study demonstrates the utility of
genome-wide expression analyses to identify novel molecu-
lar genes and pathways associated with COPD cachexia.
Specifically, our results indicated genes involved in heme
biosynthesis and metabolism were significantly downregu-
lated in cachectic patients with COPD. These results high-
light impaired heme metabolism and biosynthesis as
potential mechanisms for COPD cachexia pathogenesis via
free iron build up, oxidative tissue damage, and aberrant
repair. Further studies are warranted to determine poten-
tial efficacy of therapeutic targeting to prevent, attenuate,
or even possibly reverse COPD cachexia.
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